Molecular pathogenesis of human CD59 deficiency
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received March 21, 2018
- Accepted in final form August 7, 2018
- First Published October 29, 2018.
Author Disclosures
- Netanel Karbian, PhD,
- Yael Eshed-Eisenbach, PhD,
- Adi Tabib, MSc,
- Hila Hoizman, BSc,
- B. Paul Morgan, PhD,
- Ora Schueler-Furman, PhD,
- Elior Peles, PhD and
- Dror Mevorach, MD
- Netanel Karbian, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yael Eshed-Eisenbach, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Adi Tabib, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hila Hoizman, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- B. Paul Morgan, PhD,
1. Roche; 2. Alexion; 3. Achillion
NONE
NONE
NONE
NONE
NONE
NONE
1. GSK (payments to University); 2. Roche; 3. Alexion; 4. Achillion
NONE
NONE
NONE
1. GSK
Medical Research Council
NONE
1. Wellcome Trust
NONE
NONE
NONE
NONE
NONE
NONE
- Ora Schueler-Furman, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Elior Peles, PhD and
NONE
NONE
NONE
Associate Editor, Journal of Cell Biology Editorial Board, ASN NEURO Editorial Board, Molecular and Cellular Neuroscience Section Head, Neuronal and Glial Biology, Faculty of 1000 Editorial Advisory Group, F1000 Research
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
The National Institute of Health, NS097428 The Israel Science Foundation
NONE
The National Institute of Health, NS097428 The Israel Science Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Dror Mevorach, MD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Consulation fees from Enlivex, a cellular therapy company.
NONE
NONE
NONE
NONE
NONE
NONE
Funding by Israel Science Foundation, 1070/15
NONE
NONE
NONE
Enlivex, a cellular therapy company (not related to this publication)
NONE
NONE
- From the Rheumatology Research Center (N.K., A.T., H.H., D.M.), Center of Rare Diseases, and Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem; The Weizmann Institute (Y.E.-E., E.P.), Rehovot, Israel; Systems Immunity Research Institute (B.P.M.), Cardiff University, Cardiff, Wales, UK; and Hebrew University (O.S.-F., D.M.), Jerusalem, Israel.
- Correspondence
Dr. Mevorach mevorachd{at}gmail.com
Article usage
Cited By...
Letters: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.ng.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.